Clinical trial · Observational
Cognitive Function After Radiation Therapy for Primary Brain Tumours
NCT04306432CI-TRIAL-00055346recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction. All types of brain tumours apart from glioblastoma will be included.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cognitive Impairment | — | UNRESOLVED | — |
| Primary Brain Tumour | Primary Brain Tumor | ONTOLOGY_EXACT | 0.98 |
| Radiation Toxicity | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cognitive tests and Patient Reported Outcomes | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Impairment of verbal learning and memory as assessed by the HVLT-r test
- timeFrame
- 10 Years
- description
- Examined by the Hopkins Verbal Learning Test revised. It will be correlated to the mean radiation dose to the hippocampus. Outcome is number of correct words (0-24)
Secondary outcomes (13)
- measure
- Processing speed I
- timeFrame
- 10 years
- description
- Examined by the Trail making Test part A (TMT\_A). Outcome for TMT\_A is time in seconds (0-120 seconds).
- measure
- Processing speed II
- timeFrame
- 10 years
- description
- Examined by the Coding from Wechsler Adult Intelligence Scale (WAIS-IV). Outcome for Coding is number of correct (within 2 minutes) (0-100)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years or older and Danish speaking. * Performance status WHO 0-2 * Capable of cooperating on testing * Tumour histology (WHO 2016 classification) of the following types: anaplastic astrocytoma (IDH mutant), diffuse astrocytoma (IDH-mutant), gemistocytic astrocytoma (IDH mutant), diffuse astrocytoma (NOS), oligodendroglioma, meningioma, medulloblastoma (NOS), pituitary adenoma, other brain tumours including skull base sarcomas Exclusion Criteria: * Glioblastoma * Performance status 3-4 (Karnofsky Performances of 60 or less)
References
Publications (0)
Data not yet available
No reference posted for this study.